Integrated functional genomic screening to bypass TKI resistance in chronic myeloid leukemia

Tumas Beinortas; Brian J P Huntly

doi:10.1016/j.xcrm.2024.101565

Integrated functional genomic screening to bypass TKI resistance in chronic myeloid leukemia

Cell Rep Med. 2024 May 21;5(5):101565. doi: 10.1016/j.xcrm.2024.101565.

Authors

Tumas Beinortas¹, Brian J P Huntly²

Affiliations

¹ Department of Haematology, University of Cambridge, Cambridge, UK; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK; Cambridge University Hospitals, Cambridge, UK.
² Department of Haematology, University of Cambridge, Cambridge, UK; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK; Cambridge University Hospitals, Cambridge, UK. Electronic address: [email protected].

Abstract

CML is readily treatable with tyrosine kinase inhibitors (TKIs); however, resistance occurs, with the disease curable in only ∼15%-20% of patients. Using integrated functional genomics, Adnan Awad et al.¹ identify agents effective against CML stem cells and describe mechanisms underlying TKI resistance.

MeSH terms

Drug Resistance, Neoplasm* / drug effects
Drug Resistance, Neoplasm* / genetics
Genomics* / methods
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / pathology
Protein Kinase Inhibitors* / pharmacology
Protein Kinase Inhibitors* / therapeutic use

Substances

Protein Kinase Inhibitors